Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chengdu Anticancer Bioscience Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 2 examiners within 1 art unit, which keeps the technical setting consistent while introducing separate examiner analyses.
NESTOR, DONNA MICHELLE is the busiest examiner, with 1 pending matter. A shared technical record may be useful, but responses should remain tailored to the examiner-specific treatment of the claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| ZEMAN, MARY K | 1 | 58.9% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | — |
| 18386435 | METHODS AND MODELS FOR DIRECT MOLECULAR CONFORMATION GENERATION | ZEMAN, MARY K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | — |
| 18386435 | METHODS AND MODELS FOR DIRECT MOLECULAR CONFORMATION GENERATION | ZEMAN, MARY K | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18386435 | METHODS AND MODELS FOR DIRECT MOLECULAR CONFORMATION GENERATION | ZEMAN, MARY K | — | §101§102§103 | Non-Final OA | — | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChengdu Anticancer Bioscience Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Donna Michelle Nestor has the most, with 1 of Chengdu Anticancer Bioscience Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
